Jesús S. Mora
search externally: | Google Scholar, Springer, CiteSeer, Microsoft Academic Search, Scirus , DBlife |
Lecture:
keynote Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: Results from a randomized controlled phase 3 trial as author at European Network to Cure ALS (ENCALS), Ljubljana 2017, together with: Olivier Hermine, Luis Barbeito, 3005 views |